Business
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from
About this update from Gilead Sciences, Inc.
[{"type":"text","content":"\n– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment –\n\n\n– Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention –\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities affected by HIV, notable late-breaking abstracts include Phase 3 results from the ARTISTRY-1 and ARTISTRY-2 trials that explored the efficacy and safety of an investigational, single-tablet combination regimen of bictegravir and lenacapavir for HIV treatment.\n\n\n“Striving for continuous progress in HIV means delivering transformative therapies that support people across their entire treatment journey, aiming for sustained long-term health,” said Jared Baeten, MD, PhD, Senior Vice President, Clinical Development, Virology Therapeutic Area Head, Gilead Sciences. “Our commitment to ending the HIV epidemic globally fuels our scientific innovation and our goal to develop novel options that are responsive to the needs and preferences of people with HIV.”\n\n\nHIV Treatment Research\n\n\nAt CROI 2026, Gilead will present data showing how new regimens can potentially expand options and optimize HIV treatment.\n\n\nResults from the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials will highlight the efficacy and safety of an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) in people living with HIV who are virologically suppressed and switched from their prior antiretroviral therapy to the novel combination. Both studies were selected to be in the late-breaking abstract program. The findings provide further detail on the positive topline results from ARTISTRY-1 and ARTISTRY-2 announced in November and December 2025.\n\n\nAdditional research will expand scientific understanding of Gilead’s exploratory HIV treatment combinations, including:\n\n\n\n96-week viral su...